- Global Pharma News & Resources

USD 46,385 Mn Rvenue in Bristol Myers Squibb Company Profile | News, Rankings – Competitive Intelligence Report by

Pune, Maharashtra, India, October 10 2022 (Wiredrelease) Prudour Pvt. Ltd –:Bristol-Myers Squibb Company is a global pharmaceutical and biopharmaceutical company. The company produces innovative medicines for patients with serious diseases. Bristol-Myers Squibb has a diversified product portfolio that includes prescription medications, over-the-counter products, and nutritional supplements. Bristol-Myers Squibb was founded in 1887 by William E. Bristol and John Myers. The company’s first product was Salicin, a pain reliever extracted from willow bark. In 1889, the company began selling its products in the United States. Bristol-Myers Squibb has been a pioneer in the development of new medicines. The company’s research and development efforts have led to the discovery of many important drugs, including aspirin, digitalis, quinine, and Taxol.

Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, Revenue (US$ Mn), Operating Income (US$ Mn), Net Income (US$ Mn), SWOT Analysis, detailed reports on mergers and acquisitions (M&A), divestments, capital raising, venture capital investments, ownership and partnership transactions undertaken by Bristol Myers Squibb Company – Mergers & Acquisitions (M&A), Partnerships & Alliances 

Key Financials
Revenue (US$ Mn)

US$ 46,385 Mn was the annual revenue generated by Bristol Myers Squibb Co. in 2021

Bristol Myers Squibb Co.’s annual revenue for 2020 was US$ 42,518 Mn, a 62.62% increase from 2019

From 2018’s annual revenues, Bristol Myers Squibb Co. registered a 15.89% increase in 2019, amounting to US$ 26,145 Mn

Total revenue of US$ 22,561 Mn was generated in 2018 by Bristol Myers Squibb Co.

Grow your Business with our company Profile | Invest here:

Key Highlights

This report includes Bristol Myers Squibb Company – Mergers & Acquisitions (M&A), Partnerships & Alliance’s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.

The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Bristol Myers Squibb Company – Mergers & Acquisitions (M&A), Partnerships & Alliances. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.

Reasons to buy

– Access comprehensive financial deals data along with charts and graphs covering M&A, private equity, and partnerships and alliances.

– Form an independent opinion about Bristol Myers Squibb Company – Mergers & Acquisitions (M&A), Partnerships & Alliances’s growth strategies through the organic and inorganic activities.

– Track your competitor’s business structure and growth strategies.

More Insightful Information-

Table of Content

Business Description

Key Financials

SWOT Analysis

BMS has a robust focus on research and development (R&D).
A strong alliance and collaboration network to support drug development and commercialization
Higher returns for shareholders due to improved financial performance


Increasing liabilities pose operational risk
Litigations can damage the company’s image


Collaborations and acquisitions in clinical research are likely to increase BMS’s product range
Opportunities for BMS A positive outlook for the global pharmaceutical sector provides opportunities

Delayed launches could affect the company’s business
Increased price pressure
The company may see a decrease in its revenues if it changes the product labelling.

Key Developments
Year 2021
Year 2020
Year 2019
Year 2018

This content has been published by Prudour Pvt. Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 10-Oct-2022